Agenda
GI/Pancreas/NET/Liver Cancer SPORE Investigator's Meeting Agenda
January 11-12, 2024, in Phoenix, AZ
(Please note, the following times are approximate and all times are MST)
| DAY 1: Thursday, January 11, 2024 | ||
| 8:30-8:50 am | Welcome & Opening Remarks | Tanios Bekaii-Saab Mayo Clinic |
| 8:50-9:00 am | Report on status of GI/Pancreatic Cancer SPORE portfolio and program-related issues | Steven F. Nothwehr National Cancer Institute |
| 9:00-9:30 am | Overview of the new Washington Univ. Pancreatic Cancer SPORE + 5 min Q&A | David DeNardo Washington University School of Medicine in St. Louis Pancreatic Cancer SPORE |
| Precision Therapy — Moderator: Robert Coffey (part 1) | ||
| 9:30-9:50 am | Therapeutic approaches to fibrolamellar hepatocellular carcinoma | Sandy Simon The Rockefeller University Mayo Clinic Hepatobiliary Cancer SPORE |
| 9:50-10:10 am | Small molecule targeting of canonical STAT3 signaling to treat HCC |
David Tweardy MD Anderson Cancer Center Hepatocellular Carcinoma SPORE |
| 10:10-10:30 am | Targeting stress-induced MK2 as a novel strategy in pancreatic cancer | Kian H. Lim Washington University in St. Louis Pancreatic Cancer SPORE |
| 10:30-10:50 am | Break | |
| 10:50-11:10 am | A Systematic NEN spheroid drug screen reveals a novel drug resistance mechanism in small bowel NETs | Po Hien Ear University of Iowa Health Care NET SPORE |
| 11:10-11:25 am | Mechanism of action of mutant IDH1 inhibition | Early Stage: Meng-Ju Wu DF/HCC GI Cancer SPORE |
| 11:25-11:45 am | Metabolism-Mediated Resistance to Ferroptosis in Liver Cancer | Ju-Seog Lee MD Anderson Cancer Center Hepatocellular Carcinoma SPORE |
| 11:45-12:05 pm | Discovery of Druggable Novel Interactions with LCK in Cholangiocarcinoma Using Proximity-Dependent Biotinylation | Rory Smoot Mayo Clinic Hepatobiliary Cancer SPORE |
| 12:05-12:20 pm | Targeting MYC in colorectal cancer | Early Stage: Brian Grieb Vanderbilt University Medical Center GI Cancer SPORE |
| 12:20-1:00 pm | Lunch | |
| Precision Therapy — Moderator Eileen O'Reilly (part 2) | ||
| 1:00-1:20 pm | Targeting autophagy for the treatment of KRAS-mutant pancreatic cancer | Kirsten Bryant University of North Carolina Pancreatic Cancer SPORE |
| 1:20-1:40 pm | Prospective validation of PurIST subtyping in metastatic pancreatic cancer | Ashwin Somasundaram University of North Carolina Pancreatic Cancer SPORE |
| 1:40- 2:00 pm | Mapping colorectal cancer evolution and immune exclusion from spatial heterogeneity | Ken Lau Vanderbilt University Medical Center GI Cancer SPORE |
| 2:00-2:15 pm | Stroma reprogramming by FAK overcomes resistance to MAPK inhibition and increases responses to therapy in PDAC | Early Stage: Xiuting Liu Washington University Pancreatic Cancer SPORE |
| 2:15-3:15 pm | Tour of Mayo Arizona Research Facilities | Afton Glander Operations Manager (Mark Zobitz to escort from Waugh to 6th Floor) |
| 3:15-3:35 pm | The development of biparatopic antibodies targeting FGFR2 | William Sellers Broad Institute (DF/HCC GI Cancer SPORE) |
| 3:35-3:55 pm | Therapeutic Targeting of TGFβ addiction in Esophageal Adenocarcinoma | Eva Selfridge and Kishore Guda Case Western Reserve University GI Cancer SPORE |
| Precursor Lesions, Early Detection, and Interception — Moderator: Anirban Maitra | ||
| 3:55-4:10 pm | System-wide determination of the ERKregulated transcriptome and phosphoproteome driving KRAS-dependent pancreatic cancer | Channing Der University of North Carolina Pancreatic Cancer SPORE |
| 4:10-4:30 pm | A functional framework to interpret CDKN2A variation | Nicholas Roberts John Hopkins GI Cancer SPORE |
| 4:30-4:50 pm | Investigating the intra-tumoral microbiome in colorectal cancer across racial and ethnic groups | Meredith Hullar Fred Hutch Cancer Center Cancer Health Colorectal Cancer Disparities P20 |
| 4:50-5:10 pm | Neoantigen discovery in MMR-deficient carcinogenesis: opportunities for cancer interception | Eduardo Vilar-Sanchez MD Anderson Cancer Center GI Cancer SPORE |
| Cancer Immunology and Immune Microenvironment — Moderator: David DeNardo (continued on day 2) | ||
| 5:10-5:30 pm | Potential roles for EVs and supermeres in immuneexclusion in microsatellite stable colorectal cancer | Robert Coffey Vanderbilt School of Medicine GI Cancer SPORE |
| 7:00 pm 7:45 pm |
Social Hour Dinner |
Meritage - An Urban Tavern Marriott Phoenix Desert Ridge Resort & Spa 5350 East Marriott Drive Phoenix, AZ 85054 |
| DAY 2: Friday, January 12, 2024 | ||
| 8:05-8:10 am | Welcome to Day 2 | Mark McNiven |
| Cancer Immunology and Immune Microenvironment — Moderator: David DeNardo | ||
| 8:10-8:30 am | Harnessing the immune consequences of BRAF or KRAS inhibition in CRC | Ryan Corcoran DF/HCC GI Cancer SPORE |
| 8:30-8:50 am | Role of neutrophils and their NETs in pancreatic cancer metastasis | Vidhi Chandra MD Anderson Cancer Center GI Cancer SPORE |
| 8:50-9:05 am | Immunobiological factors that contribute to pancreatic cancer aggressiveness and cancer health disparities | Early Stage: Janielle Maynard John Hopkins University GI Cancer SPORE |
| 9:05-9:25 am | Finding the right MET-hod to potentiate PD-1 blockade in HCC | Michael Curran MD Anderson Cancer Center Hepatocellular Carcinoma SPORE |
| 9:25-9:45 am | Mutant KRAS-targeted vaccine immunotherapy for pancreatic and colorectal cancers | Neeha Zaidi John Hopkins University GI Cancer SPORE |
| 9:45-10:00 am | Additive and subtractive microbial modulation strategies to augment response to therapy in colorectal cancer | Early Stage: Michael White MD Anderson Cancer Center GI Cancer SPORE |
| 10:00-10:20 am | GRACE: gastric immune response and cancer interception | Meira Epplein & Katherine Garman Duke Cancer Institute Cancer Health Disparities P20 |
| 10:20-10:40 am | 10:20-10:40 am Break | |
| 10:40-11:00 am | DNA Damage Repair Enhances Immunogenicity for Pancreatic Cancer | Wungki Park Memorial Sloan Kettering Cancer Center Pancreatic Cancer SPORE |
| 11:00-11:20 am | Tumor immune microenvironment remodeling by combination DNA- and histonemethyltransferase inhibition | Michael Topper John Hopkins Medicine Epigenetics Therapies SPORE |
| 11:20-11:40 am | Immunomodulation in pancreatic cancer | Kevin Soares Memorial Sloan Kettering Cancer Center Pancreatic Cancer SPORE |
| 11:40-11:55 am | Engineering recombinant IL33 for pancreatic cancer immunotherapy | Early Stage: Masataka Amisaki Memorial Sloan Kettering Cancer Center Pancreatic Cancer SPORE |
| 11:55-12:15 pm | Improving on Immune Checkpoint Blockade Therapy for HCC with Viroimmunotherapy | Richard Vile Mayo Clinic Hepatobiliary Cancer SPORE |
| 12:15-12:20 pm | Closing Remarks | Steven F. Nothwehr |